Modelon remains steadfast in its efforts to enhance the capabilities for cloud scaling in its product development, as per its previously established plans. The planned release of the significantly. | May 17, 2023
Redeye provides an update on Kontigo Care following its Q1 2023 report. The report indicates a slightly weaker performance than anticipated. Still, we are optimistic about the impact of price. | May 17, 2023
Redeye leaves a comment on the Q1 report published by Alzinova earlier today. Overall, the report was in line with our expectations. However, we are encouraged by the clinical and financial progress. | May 17, 2023
Redeye comments on Klaria Pharma’s Q1 2023 report. The company reports continued validation of its epinephrine alginate film. We regard The Swedish Financial Supervisory Authority´s. | May 16, 2023
Redeye updates its view post Fragbite Groups Q1 2023 report, where net sales came in stronger than expected, but profitability was a tad soft due to higher investments across its organization.. | May 15, 2023